NVO241108P143000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Trump sparks a rally in the US dollar! US stocks and bitcoin hit new highs, with the Dow rising 1500 points, small cap stocks surging, while US bonds and metals plummet.
Dow rises to the best level in two years, small cap index rises nearly 6%, banking stocks rise over 10%, oil, steel, and crypto stocks surge, European and American solar stocks all collapse, Trump media technology rises by almost 35% before closing up by about 6%, Tesla rises by nearly 15% to a two-year high, Qualcomm rises by 10% after the bell. Chinese concept stocks narrow their declines, NIO Inc and Zeekr drop over 5%. 10-year US Treasury yield rises the most by 20 basis points nearing 4.48%, reaching a four-month high along with a 1.7% rise breaking 105 in the USD index, Bitcoin rises by 9% nearing $0.076 million, offshore RMB drops by a thousand points to below 7.20, a three-month low, Euro and Yen once fell by 2%. Gold drops over 3%, London copper drops over 4%.
Novo Nordisk warns of the risks of compound generic drugs, stating that 10 people have died and over a hundred have been hospitalized.
①Novo-Nordisk's chief financial officer stated that 10 people have died after taking the compound generic weight-loss drug, with another 100 hospitalized. ②Novo-Nordisk has requested the FDA to list semaglutide in the "Provable Synthetic Difficulty List" to restrict generic production, and the company will continue to engage in dialogue with the FDA to address pharmaceutical accessibility issues.
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Trending: Novo Nordisk Posts Higher 3Q Profit
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
Novo Nordisk Analyst Ratings
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs -- Barrons.com
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Express News | Novo Nordisk's chief financial officer expects the sales growth rate in 2025 to reach over ten percent.
Novo Nordisk CFO Sees 2025 Sales Growth Could Be In High Teens
Novo Nordisk Execs Were Speaking on Call After 3Q Earnings
Novo Nordisk CEO: We Are Scaling Significantly to Sustain Attractive Growth Profile
Novo Nordisk CFO: Don't Expect Major Reversal Of Inventories Into 4Q
Novo Nordisk Head of Devt: Expect to See Unsurpassed Weight-Loss With CagriSema
Novo Beats Eli Lilly in Q3 Sales for Obesity Drug